19
Aug

Eli Lilly has won a “tentative” FDA approval for its knockoff of Sanofi’s Lantus, but don’t look for it at a pharmacy anytime soon. The insulin glargine injection–to be marketed as Basaglar eventually in the U.S.–faces an automatic 30-month stay after Sanofi filed a suit against Lilly and its partner Boehringer Ingelheim claiming patent infringement.

…read more

Source: Lilly grabs a ‘tentative’ FDA OK for insulin treatment, but Sanofi still blocks its path

    

0 No comments